Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., listed on Nasdaq under the ticker UPTD, filed its annual report on Form 10-K with the SEC on March 14, 2023, covering fiscal year 2022. The company is a clinical-stage biopharmaceutical firm operating in the immunotherapy segment of the healthcare sector, focused on developing novel treatment candidates. The 10-K filing reflects its status as a publicly traded entity following its SPAC business combination, placing it among the cohort of life-sciences companies that accessed public markets through blank-check structures in recent years. For the full SPAC deal history, financials, and real-time filing alerts on UPTD and hundreds of other names, sign up for SpacDesk at spacdesk.com.